Astaxanthin

Phase 3Small molecule

SSheba Medical Center

Astaxanthin is one of 44 small molecule programs targeting Pneumonia. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

PneumoniaRecruiting

HumansUnknown status

PneumoniaPhase 3

Recruiting

HumansPreclinical

Unknown status

Competition

Competitive Landscape

152 competitors in Pneumonia

#DrugCompanyPhaseTrials

Astaxanthin

SSheba Medical Center

Phase 3

1 2

Acanya

Pfizer

Preclinical

1 3

Prevacid

Takeda

Preclinical

1 4

Plaquenil

Jazz Pharmaceuticals

Preclinical

1 5

Innohep

Jazz Pharmaceuticals

Preclinical

1 6

Zantac 150

CChattem

Preclinical

2 7

Mycifradin

PPharmacia and Upjohn

Preclinical

1 8

Ofev

Boehringer Ingelheim

Preclinical

1 9

Mucinex

RReckitt Benckiser LLC

Preclinical

1 10

Cancidas

FFresenius Kabi Taiwan Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Osteoarthritis2 trials

Astaxanthin for Management of Inflammation in Knee Osteoarthritis

Terminated·PPrisma Health-Midlands·Phase 2/3·NCT05138549·16 enrolled

Effect of Astaxanthin in Moderate to Severe Knee Osteoarthritis

Completed·—·Phase 2·NCT05437601·80 enrolled

Diabetic Neuropathy1 trial

The Benefits of Astaxanthin as Add on Therapy in the Management of Painful Diabetic Neuropathy Patient

Unknown status·—·Phase 2/3·NCT04689984·60 enrolled

Pneumonia1 trial

Study of the Efficacy and Safety of Antioxidants Astaxanthin as an Adjuvant Therapy for Community Acquired Pneumonia Patients.

Recruiting·FFuture University in Egypt·Phase 4·NCT06334874·80 enrolled

Humans1 trial

Physiological and Molecular Influences of Astaxanthin Supplementation on Heat Strain in Humans

Unknown status·SSheba Medical Center·N/A·NCT02088242·34 enrolled

Amyotrophic Lateral Sclerosis (ALS)1 trial

ROAR-DIGAP: A Widely Inclusive, Largely Virtual Pilot Trial Utilizing DIGAP (Deep Integrated Genomics Analysis Platform) To Personalize Treatments

Completed·DDuke University·Phase 2·NCT06429059·50 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for Astaxanthin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Astaxanthin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Astaxanthin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sheba Medical Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: SSheba Medical Center

Astaxanthin

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Osteoarthritis2 trials

Diabetic Neuropathy1 trial

Pneumonia1 trial

Humans1 trial

Amyotrophic Lateral Sclerosis (ALS)1 trial

References

Drug Info

Quick Facts

Related News